Tumor Angiogenic Inhibition Triggered Necrosis (TAITN) in Oral Cancer.
Adult
Aged
Aged, 80 and over
Animals
Benzylamines
Carcinoma, Squamous Cell
/ drug therapy
Cell Line, Tumor
Cyclams
Female
Heterocyclic Compounds
/ pharmacology
Humans
Male
Mice
Mice, Inbred BALB C
Mice, Nude
Middle Aged
Mouth Neoplasms
/ drug therapy
Neovascularization, Pathologic
Receptors, CXCR4
/ antagonists & inhibitors
CXCR4 antagonist
hypoxia
oral squamous cell carcinoma
tumor angiogenic inhibition triggered necrosis (TAITN)
tumor blood vessel
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
22 07 2019
22 07 2019
Historique:
received:
27
06
2019
revised:
18
07
2019
accepted:
20
07
2019
entrez:
25
7
2019
pubmed:
25
7
2019
medline:
25
2
2020
Statut:
epublish
Résumé
CXCR4 is a chemokine receptor crucial in tumor progression, although the angiogenic role of CXCR4 in oral squamous cell carcinoma (OSCC) has not been investigated. Here we show that CXCR4 is crucial for tumor angiogenesis, thereby supporting tumor survival in OSCC. Immunohistochemistry on human clinical specimens revealed that CXCR4 and a tumor vasculature marker CD34 were co-distributed in tumor vessels in human OSCC specimens. To uncover the effects of CXCR4 inhibition, we treated the OSCC-xenografted mice with AMD3100, so-called plerixafor, an antagonist of CXCR4. Notably, we found a unique pathophysiological structure defined as tumor angiogenic inhibition triggered necrosis (TAITN), which was induced by the CXCR4 antagonism. Treatment with AMD3100 increased necrotic areas with the induction of hypoxia-inducible factor-1α in the xenografted tumors, suggesting that AMD3100-induced TAITN was involved in hypoxia and ischemia. Taken together, we demonstrated that CXCR4 plays a crucial role in tumor angiogenesis required for OSCC progression, whereas TAITN induced by CXCR4 antagonism could be an effective anti-angiogenic therapeutic strategy in OSCC treatment.
Identifiants
pubmed: 31336612
pii: cells8070761
doi: 10.3390/cells8070761
pmc: PMC6678844
pii:
doi:
Substances chimiques
Benzylamines
0
CXCR4 protein, human
0
Cyclams
0
Heterocyclic Compounds
0
Receptors, CXCR4
0
plerixafor
S915P5499N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Cell. 2005 May 6;121(3):335-48
pubmed: 15882617
Ann Surg Oncol. 2017 Mar;24(3):832-840
pubmed: 26577115
Nat Med. 1998 Jan;4(1):72-7
pubmed: 9427609
J Immunol. 2003 Feb 1;170(3):1136-40
pubmed: 12538668
Blood. 2000 Feb 1;95(3):756-68
pubmed: 10648383
J Neurooncol. 2005 Sep;74(3):287-93
pubmed: 16132525
Am J Pathol. 1999 Apr;154(4):1125-35
pubmed: 10233851
J Clin Oncol. 2009 Oct 1;27(28):4767-73
pubmed: 19720922
Lab Invest. 2006 Dec;86(12):1221-32
pubmed: 17075581
Breast Cancer Res. 2003;5(2):83-8
pubmed: 12631386
Antimicrob Agents Chemother. 2000 Jun;44(6):1667-73
pubmed: 10817726
Tumour Biol. 2014 Aug;35(8):7765-73
pubmed: 24810923
J Clin Invest. 2010 Mar;120(3):694-705
pubmed: 20179352
Nature. 1996 Aug 29;382(6594):829-33
pubmed: 8752280
Nature. 2001 Mar 1;410(6824):50-6
pubmed: 11242036
Respir Res. 2002;3:26
pubmed: 12537605
PLoS One. 2012;7(1):e28305
pubmed: 22279523
Int J Oncol. 2004 Jul;25(1):65-71
pubmed: 15201990
J Biol Chem. 1998 Feb 13;273(7):4282-7
pubmed: 9461627
Br J Cancer. 2006 Jul 17;95(2):210-7
pubmed: 16819541
Biochem Biophys Res Commun. 2008 Jun 27;371(2):283-8
pubmed: 18435916
Cytokine. 1991 May;3(3):189-94
pubmed: 1883957
Adv Immunol. 2000;74:127-80
pubmed: 10605606
Leukemia. 2013 Jan;27(1):24-31
pubmed: 22951944
Immunology. 1999 Sep;98(1):36-41
pubmed: 10469231
Semin Cancer Biol. 2004 Jun;14(3):181-5
pubmed: 15246053
Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7
pubmed: 24277834
PLoS One. 2013 Nov 13;8(11):e80773
pubmed: 24236200
Blood. 2008 Aug 15;112(4):990-8
pubmed: 18426988
Angiogenesis. 2017 Nov;20(4):409-426
pubmed: 28660302
Eur J Cancer. 2011 Feb;47(3):452-9
pubmed: 20965717
Eur J Immunol. 1999 Jun;29(6):1823-31
pubmed: 10382744
Science. 1983 Sep 23;221(4617):1283-5
pubmed: 6612342
J Immunol. 2002 Aug 1;169(3):1277-82
pubmed: 12133949
Biochem Biophys Res Commun. 2007 Aug 3;359(3):716-22
pubmed: 17559806
J Exp Med. 2005 Apr 18;201(8):1307-18
pubmed: 15837815
Nature. 1998 Jun 11;393(6685):591-4
pubmed: 9634237
Microcirculation. 2003 Jun;10(3-4):265-72
pubmed: 12851644
Neurosurgery. 2007 Sep;61(3):570-8; discussion 578-9
pubmed: 17881971
Front Cell Neurosci. 2014 May 28;8:144
pubmed: 24904289
Am J Clin Pathol. 1991 Jul;96(1):25-31
pubmed: 1712541
Antimicrob Agents Chemother. 1994 Apr;38(4):668-74
pubmed: 7913308
Oncol Rep. 2009 Mar;21(3):707-12
pubmed: 19212630
Strahlenther Onkol. 2016 Jan;192(1):47-54
pubmed: 26374452
Oncogene. 2016 Feb 18;35(7):816-26
pubmed: 25961926
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1925-30
pubmed: 9050881
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Curr Pharm Des. 2009;15(29):3396-416
pubmed: 19860687
Gastroenterology. 1999 Aug;117(2):359-67
pubmed: 10419917